Chemotherapy for recurrent cervical carcinoma

Current Opinion in Oncology

Volumn 18, Issue 5, 2006, Pages 516-519

  Moore, David H ^a  

^a Gynecologic Oncology of Indiana   (United States)

Author keywords

Cervical cancer; Chemotherapy; Clinical trials; Paclitaxel; Platinum; Topotecan

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; IPROPLATIN; METHOTREXATE; MITOLACTOL; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; TOPOTECAN; VINBLASTINE;

BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOPULMONARY INSUFFICIENCY; CLINICAL TRIAL; COMA; GASTROINTESTINAL TOXICITY; HUMAN; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEIZURE; SOMNOLENCE; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; QUALITY OF LIFE; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS;

EID: 33746900407     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000239893.21161.51     Document Type: Review

References (30)

1. Thigpen JT, Shingleton H, Homesley H, et al. cis-Platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: A phase II trial of the Gynecologic Oncology Group. Cancer 1981; 48:899-903.
2. Bonomi P, Blessing JA, Stehman FB, et al. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix - a Gynecologic Oncology Group study. J Clin Oncol 1985; 3:1079-1085.
3. Thigpen JT, Blessing JA, DiSaia PJ, et al. A randomized comparison of rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1989; 32:198-202.
4. McGuire WP, Arseneau JC, Blessing JA, et al. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix - a Gynecologic Oncology Group study. J Clin Oncol 1989; 7:1462-1468.
5. Stehman FB, Blessing JA, McGehee R, Barrett RJ. A phase II evaluation of mitolactol in carcinoma of the cervix. J Clin Oncol 1989; 7:1892-1895.
6. Coleman RE, Harper PG, Gallagher C, et al. A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix. Cancer Chemother Pharmacol 1986; 18:280-283.
7. Meanwell CA, Mould JJ, Blackledge G, et al. Phase II study of ifosfamide in cervical cancer. Cancer Treat Rep 1986; 70:727-730.
8. Sutton GP, Blessing JA, McGuire WP, et al. Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1993; 168:805-807.
9. Omura GA, Blessing JA, Vaccarello L, et al. A randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1997; 15:165-171.
10. Bloss JD, Blessing JA, Behrens BC, et al. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 2002; 20:1832-1837.
11. McGuire WP, Blessing JA, Moore DH, et al. Paclitaxel has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group study. J Clin Oncol 1996; 14:792-795.
12. Rose PG, Blessing JA, Gershenson DM, McGehee R. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1999; 17:2676-2680.
13. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 2004; 22:3113-3119.
14. Muderspach LI, Blessing JA, Levenback C, et al. A phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2001; 81:213-215.
15. Johnson RK, McCabe FL, Yu Y. Combination regimens with topotecan in animal tumor models. Ann Oncol 1992; 3:85 (Abstract).
16. Long HJ, Cross WG, Wieand HS, et al. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent carcinoma of the uterine cervix and vagina. Gynecol Oncol 1995; 57:235-239.
17. Papadimitriou CA, Dimopoulos MA, Giannakoulis N, et al. A phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of metastatic carcinoma of the uterine cervix. Cancer 1997; 79:2391-2395.
18. Murad AM, Medina L, Andrade CA, et al. Phase II open label multicentric trial of MVAC - methotrexate (M), vinblastin (V), doxorubicin (A), and cisplatin (C) plus granulocyte colony stimulating factor (Filgrastim) in advanced recurrent cervical carcinoma: final report. Proc ASCO 1995; 14:276 (Abstract).
19. Long HJ, Bundy BN, Grendys EC, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 2005; 23:4626-4633. This was the first prospective randomized trial in advanced/metastatic cervical carcinoma to demonstrate a survival advantage for combination chemotherapy (cisplatin plus topotecan) over cisplatin alone.
20. ••], this study showed that cisplatin plus topotecan resulted in greater acute toxicity but did not diminish quality of life when compared with single-agent cisplatin.
21. Smith HO, Jiang CS, Weiss GR, et al. Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study. Int J Gynecol Cancer 2006; 16:298-305. This phase II trial demonstrated a 5% response rate to cisplatin plus tirapazamine in patients who had previously received chemotherapy concurrent with radiation therapy.
22. Morris M, Brader KR, Levenback C, et al. Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix. J Clin Oncol 1998; 16:1094-1098.
23. Lhommé C, Vermorken JB, Mickiewicz E, et al. A Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynecological Cancer Cooperative Group study. Eur J Cancer 2000; 36: 194-199.
24. Morris M, Blessing JA, Monk BJ, et al. Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 2004; 22:3340-3344.
25. Schilder RJ, Blessing JA, Morgan M, et al. Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2000; 76:204-207.
26. Peters GJ, Bergman AM, Ruiz van Halperen VW, et al. Interactions between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995; 22:72-79.
27. Duenas-Gonzalez A, Lopez-Graniel C, Gonzalez A, et al. A phase II study of gemcitabine and cisplatin combination as induction chemotherapy of untreated locally advanced cervical carcinoma. Ann Oncol 2001; 12:541-547.
28. Burnett AF, Roman LD, Garcia AA, et al. A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix. Gynecol Oncol 2000; 76:63-66.
29. Lorvidhaya V, Chitaparanarux I, Kamnerdpaphon P. Gemcitabine and cisplatin in patients with metastatic cervical cancer [Abstract #1554]. Proc ASCO 2000; 19:39.
30. Mahouf H, Bouzid K. Gemcitabine and cisplatin in recurrent, advanced or metastatic cervical squamous cell carcinoma [Abstract #801]. Proc ASCO 2001; 20:207.